---
title: Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy
nct_id: NCT00952848
overall_status: COMPLETED
phase: PHASE2
sponsor: Virginia Commonwealth University
study_type: INTERVENTIONAL
primary_condition: Chemotherapeutic Agent Toxicity
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00952848.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00952848"
ct_last_update_post_date: 2017-03-29
last_seen_at: "2026-05-12T06:44:28.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy

**Official Title:** The Efficacy of MC5-A ("Scrambler") Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Phase II Pilot Trial

**NCT ID:** [NCT00952848](https://clinicaltrials.gov/study/NCT00952848)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 18
- **Lead Sponsor:** Virginia Commonwealth University
- **Collaborators:** National Cancer Institute (NCI)
- **Conditions:** Chemotherapeutic Agent Toxicity, Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
- **Start Date:** 2009-06-12
- **Completion Date:** 2010-06
- **CT.gov Last Update:** 2017-03-29

## Brief Summary

RATIONALE: Electronic stimulation using a MC5-A Scrambler may help relieve pain in patients who develop peripheral neuropathy while undergoing chemotherapy treatments for cancer.

PURPOSE: This phase II trial is studying how well MC5-A Scrambler therapy works in reducing peripheral neuropathy caused by chemotherapy.

## Detailed Description

OBJECTIVES:

Primary

* To determine if MC5-A Scrambler therapy will improve the pain associated with chemotherapy-induced peripheral neuropathy in cancer patients by 20%.

Secondary

* To evaluate the effect of MC5-A therapy on specific pain and neuropathy scales.
* To evaluate the effect of MC5-A therapy on overall quality of life.
* To evaluate the effect of MC5-A therapy on other pain drugs used.
* To evaluate the toxicities of MC5-A therapy.

OUTLINE: Patients undergo gel electrode application on the skin in the most pain-free of the pain-affected area. Patients undergo treatment with the MC5-A Scrambler machine over 60 minutes once daily on days 1-10. On day 1, the treatment intensity is increased every 10 minutes to the maximum intensity individually bearable by the patient without any input of pain or discomfort. The patient should feel the disappearance of the pain during treatment as a sign that the proper nerve pathway(s) has (have) been correctly identified. Subsequent treatments begin at the highest intensity tolerated at the previous treatment. Patients with no improvement after 3 treatments discontinue treatment.

Patients complete questionnaires about symptoms, pain, and quality of life periodically.

After completion of study treatment, patients are followed up at 2 and 4 weeks, monthly for 3 months, and at 6 months.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 120 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
DISEASE CHARACTERISTICS:

* Chemotherapy-induced peripheral neuropathy (CIPN) meeting the following criteria:

  * More than 4 weeks since prior neurotoxic chemotherapy including taxanes (e.g., paclitaxel or docetaxel), platinum-based compounds (e.g., carboplatin, cis-platinum, oxaliplatin), vinca-alkaloids (e.g., vincristine, vinblastine, or vinorelbine), or proteosome inhibitors (e.g., bortezomib)
  * Pain or symptoms of peripheral neuropathy for ≥ 1 month attributed to CIPN
  * Pain stable for ≥ 2 weeks
  * Average daily pain rating of ≥ 5 out of 10 using the pain numerical rating scale (0 is no pain and 10 is worst pain possible)
* No symptomatic brain metastases

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Life expectancy ≥ 3 months
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No history of an allergic reaction or intolerance to transcutaneous electronic nerve stimulation
* No pacemaker or implantable drug-delivery system (e.g., Medtronic Synchromed)
* No heart stent or vena cava clips
* No history of epilepsy or brain damage
* No other identified causes of painful paresthesias existing before chemotherapy (e.g., radiation or malignant plexopathy, lumbar or cervical radiculopathy, pre-existing peripheral neuropathy of another etiology \[e.g., B12 deficiency, AIDS, monoclonal gammopathy, diabetes, heavy metal poisoning amyloidosis, syphilis, hyperthyroidism, hypothyroidism, inherited neuropathy, etc.\])
* No skin conditions (e.g., open sores) that would prevent proper application of the electrodes
* No other medical or other conditions that, in the opinion of the investigators, might compromise the objectives of the study

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* At least 30 days since prior and no concurrent investigational agents for pain control
* More than 4 weeks since prior and no concurrent celiac plexus block or other neurolytic pain control treatment
* No prior or concurrent anti-convulsants
* No concurrent neurotoxic or potentially neurotoxic chemotherapy
* Concurrent pain treatments allowed provided the following criteria are met:

  * Pain is not satisfactorily controlled
  * Dose of the other medication has been stable for ≥ 4 weeks
```

## Arms

- **MC5-A Scramble instrument** (EXPERIMENTAL) — Treatment of chronic neuropathic pain with the MC5-A device

## Interventions

- **questionnaire administration** (OTHER) — Pain Rating Score
- **Sensory Neuropathy Scale instrument** (OTHER) — ECOG Common Toxicity Criteria for Sensory Neuropathy scale
- **Quality of Life instrument** (OTHER) — Uniscale 0-100 scale global quality of life
- **MC5-A Scrambler device** (DEVICE) — Electrical stimulation for 60 minutes

## Primary Outcomes

- **Change in Pain Score** _(time frame: 15 days)_ — Change in Neumeric Rating Score for Pain as measured by a Numeric Pain Rating scale between day 0 to day 15.

Scale is 0 (none) to 10 (severe)

## Secondary Outcomes

- **Effect of MC5-A on Pain and Neuropathy** _(time frame: 2 weeks)_
- **Effect of MC5-A on Morphine Oral Equivalent Doses Used Before and After MC5-A Therapy** _(time frame: 2 weeks)_
- **Toxicity of MC5-A Therapy on Global Quality of Life Using the Uniscale Instrument** _(time frame: 2 weeks)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00952848.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00952848*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*